GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » Price-to-Tangible-Book

Citius Pharmaceuticals (Citius Pharmaceuticals) Price-to-Tangible-Book : 7.25 (As of Apr. 25, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Citius Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-25), Citius Pharmaceuticals's share price is $0.7326. Citius Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.10. Hence, Citius Pharmaceuticals's Price to Tangible Book Ratio of today is 7.25.

The historical rank and industry rank for Citius Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

CTXR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.49   Med: 5.81   Max: 40.83
Current: 7.33

During the past 13 years, Citius Pharmaceuticals's highest Price to Tangible Book Ratio was 40.83. The lowest was 2.49. And the median was 5.81.

CTXR's Price-to-Tangible-Book is ranked worse than
82.95% of 1220 companies
in the Biotechnology industry
Industry Median: 2.67 vs CTXR: 7.33

A closely related ratio is called PB Ratio. As of today, Citius Pharmaceuticals's share price is $0.7326. Citius Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.53. Hence, Citius Pharmaceuticals's P/B Ratio of today is 1.37.


Citius Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Citius Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Price-to-Tangible-Book Chart

Citius Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 11.69 4.67 5.19 4.92

Citius Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.64 7.65 6.59 4.92 7.49

Competitive Comparison of Citius Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Citius Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Citius Pharmaceuticals's Price-to-Tangible-Book falls into.



Citius Pharmaceuticals Price-to-Tangible-Book Calculation

Citius Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=0.7326/0.101
=7.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Citius Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Pharmaceuticals (Citius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Executives
Myron Z Holubiak director, officer: Vice Chairman C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Leonard L Mazur director, 10 percent owner, officer: Chief Executive Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Suren G Dutia director C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Carol Webb director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
Eugene Myron Holuka director 11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016
Jaime Bartushak officer: Chief Financial Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Myron Czuczman officer: Chief Medical Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Howard Safir director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
William Kane director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016

Citius Pharmaceuticals (Citius Pharmaceuticals) Headlines

From GuruFocus